环磷酰胺联合泊马度胺-地塞米松治疗复发难治多发性骨髓瘤的随机MUKseven试验
MUKseven是一项英国多中心随机对照开放标签2期试验,计划入组250例但提前终止,实际104例复发难治多发性骨髓瘤患者随机接受CPd或Pd方案。主要终点PFS未达统计学显著,CPd组中位PFS 6.9个月(95%CI 5.7-10.4)vs Pd组4.6个月(95%CI 3.5-7.4),但CPd总缓解率更高且毒性可比。CPd组外周血CD3+ T细胞、HLA-DR阳性CD8+及CD8+效应记忆细胞富集更强更持久,基线CD4+ T细胞水平为PFS预后标志。
要点
- CPd较Pd提高总缓解率,PFS无显著差异,毒性可比。
- CPd增强并维持CD3+ T细胞及CD8+效应记忆细胞富集。
- 基线CD4+ T细胞水平可预测PFS。
核心结论
- 在复发难治多发性骨髓瘤中,CPd较Pd提高总缓解率并显著改变T细胞组成,但PFS无统计学显著差异。
研究设计与样本
- MUKseven(NCT02406222)为学术性、英国多中心、随机对照、开放标签2期试验,计划样本量250例。
- 2016至2018年从26家英国医院入组104例复发难治多发性骨髓瘤患者,采用最小化法随机分配至CPd或Pd组。
主要发现
- 主要终点PFS未达统计学显著:CPd组中位6.9个月(95%CI 5.7-10.4),Pd组4.6个月(95%CI 3.5-7.4),提前终止导致把握度不足。
- CPd组总缓解率更高,毒性与此前报道的Pd方案相当。
- 外周血T细胞分析显示CPd组CD3+ T细胞、HLA-DR阳性CD8+及CD8+效应记忆细胞富集更强更持久。
- 基线CD4+ T细胞水平被确定为PFS的预后标志。
关键数值与推荐
- CPd组中位PFS 6.9个月(95%CI 5.7-10.4),Pd组4.6个月(95%CI 3.5-7.4),差异无统计学意义。
临床怎么用
- CPd可作为复发难治多发性骨髓瘤的可及联合方案,总缓解率优于Pd且毒性可比。
- 基线CD4+ T细胞水平有助于PFS预后分层。
- 环磷酰胺加入Pd可增强T细胞免疫效应,支持免疫联合策略探索。
局限性
- 因标准治疗变化提前终止招募,样本量远低于计划,研究把握度不足。
- PFS差异未达统计学显著,需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There is an ongoing need for accessible combination therapies for patients with relapsed-refractory multiple myeloma (RRMM), alongside a growing interest in understanding their immunological effects, particularly on T-cell populations. Myeloma UK (MUK) MUKseven (NCT02406222) was an academic, UK multicentre randomized controlled, open-label phase 2 trial. The planned sample size was 250 patients but recruitment was stopped early due to changes in standard of care. Between 2016 and 2018, 104 RRMM patients from 26 UK hospitals were recruited and randomized to receive cyclophosphamide, pomalidomide, and dexamethasone (CPd) or pomalidomide and dexamethasone (Pd) using minimization. Fifty-four participants in each arm were analysed. The primary end-point, progression-free survival (PFS) was not met with median 6.9 months (95% Confidence Interval (CI): 5.7-10.4) for CPd versus 4.6 months for Pd (95% CI: 3.5-7.4), although not significant; reflecting underpowering from early closure. CPd showed a higher overall response rate, and toxicity was comparable to previously reported Pd regimens. Peripheral blood T-cell analysis revealed stronger and more sustained enrichment of CD3+ T cells, HLA-DR-positive CD8+ and CD8+ effector memory cells in the CPd arm. Pretreatment CD4+ T-cell levels were identified as a prognostic PFS marker. In summary, our results demonstrate significant effects of cycloaddition to Pd on response and T-cell composition.
引用
- Hall A, Croft J, Walker K, et al. Clinical and immunological effects of adding cyclophosphamide to pomalidomide-dexamethasone in relapsed-refractory multiple myeloma: The randomized MUKseven trial. Br J Haematol. 2026. PMID: 42299497. doi:10.1111/bjh.70611
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。